The company sources raw materials from approved vendors through a vendor management program. SeraCare, acquired by LGC Clinical Diagnostics, Inc., serves as the single source supplier of human plasma under a supply agreement initially established in 2014 and amended in 2018 and 2021. This agreement includes provisions for price modifications, termination rights, and indemnification. Confluent Medical Technologies, Inc. is the single source supplier of polymer mesh, with a supply agreement originally held by Biomedical Structures LLC and assigned to Confluent following its acquisition of Biomedical Structures in 2016. The agreement was amended in 2020 to incorporate price adjustments based on raw material costs and volume discounts. The company also obtains custom pre-sterilized assemblies and tubing sets from multiple approved vendors, as well as bioprocess solutions from a division of Thermo Fisher Scientific, which maintains redundant production capacity. The company is exploring additional redundant vendors for critical materials and manages vendor changes through a change control process.
Humacyte Inc's Comment on Supply Chain
The company sources raw materials from approved vendors through a vendor management program. SeraCare, acquired by LGC Clinical Diagnostics, Inc., serves as the single source supplier of human plasma under a supply agreement initially established in 2014 and amended in 2018 and 2021. This agreement includes provisions for price modifications, termination rights, and indemnification. Confluent Medical Technologies, Inc. is the single source supplier of polymer mesh, with a supply agreement originally held by Biomedical Structures LLC and assigned to Confluent following its acquisition of Biomedical Structures in 2016. The agreement was amended in 2020 to incorporate price adjustments based on raw material costs and volume discounts. The company also obtains custom pre-sterilized assemblies and tubing sets from multiple approved vendors, as well as bioprocess solutions from a division of Thermo Fisher Scientific, which maintains redundant production capacity. The company is exploring additional redundant vendors for critical materials and manages vendor changes through a change control process.
Sources:
Humacyte Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Humacyte Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
